Molecular Targeted Therapies for Hematologic Malignancies
Pp. 218-227 (10)
Protein kinase inhibition has become a promising strategy for cancer therapy since the
successful results obtained with Imatinib in the treatment of Chronic Myeloid Leukemia. Several other
compounds that target specific kinases are now in clinical development for myeloid and lymphoid
neoplasms. In this chapter we discuss the role of kinase dysregulation in hematologic malignancies and
the development of inhibitors for these targets.
Protein Kinase Inhibition Abl, PDGFR Inhibitors, Philadelphia chromosome, Acute
Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloproliferative Disorders, Imatinib,
Second Generation Abl Inhibitors, FLT3 Inhibitors, c-KIT Inhibitors, JAK2 inhibitors, Protein Kinase C
Inhibitors, Cyclin-dependent Kinase Inhibitors, mTOR inhibitors, Anaplastic Lymphoma Kinase
Inhibitors, Limitations of Molecular Targeted Therapies.
Hematology Department - Hospital de Base do Distrito Federal - Brasilia, Brazil.